{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:54:07Z","timestamp":1788976447715,"version":"build-2803163510"},"reference-count":22,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2023,3,31]]},"DOI":"10.1536\/ihj.22-441","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T22:24:47Z","timestamp":1680215087000},"page":"246-251","source":"Crossref","is-referenced-by-count":8,"title":["Safety of SGLT2 Inhibitors in Three Chronic Diseases"],"prefix":"10.1536","volume":"64","author":[{"given":"Shiyao","family":"Ge","sequence":"first","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University"},{"name":"Hebei Province Key Laboratory of Environment and Human Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruobin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University"},{"name":"Hebei Province Key Laboratory of Environment and Human Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University"},{"name":"Hebei Province Key Laboratory of Environment and Human Health"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Geng","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Bao","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Statistics, School of Public Health, Hebei Medical University"},{"name":"Hebei Province Key Laboratory of Environment and Human Health"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yamada T, Wakabayashi M, Bhalla A, <i>et al<\/i>. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol 2021; 20: 14.","DOI":"10.1186\/s12933-020-01197-z"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Li X, Zhang Q, Zhu L, <i>et al<\/i>. Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: a meta-analysis of randomized controlled trials. Int J Cardiol 2021; 332: 119-26.","DOI":"10.1016\/j.ijcard.2021.03.077"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988; 318: 1728-33.","DOI":"10.1056\/NEJM198806303182605"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med 2017; 15: 112.","DOI":"10.1186\/s12916-017-0875-8"},{"key":"5","unstructured":"5. Cochrane Hanbook for Systematic Reviews of Interventions. version 5.1.0. Identifying and Measuring Heterogeneity. Available at: http:\/\/handbook.cochrane.org\/."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Veroniki AA, Bender R, Glasziou P, Straus SE, Tricco AC. The number needed to treat in pairwise and network meta-analysis and its graphical representation. J Clin Epidemiol 2019; 111: 11-22.","DOI":"10.1016\/j.jclinepi.2019.03.007"},{"key":"7","unstructured":"7. Sackett DLHR, Guyatt GH, Tugwell P. <i>Clinical Epidemiology: A Basic Science for Clinical Medicine<\/i>. Vol. 208: Boston: Little Brown; 1991."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wiviott SD, Raz I, Bonaca MP, <i>et al<\/i>. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347-57.","DOI":"10.1056\/NEJMoa1812389"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zinman B, Wanner C, Lachin JM, <i>et al<\/i>. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117-28.","DOI":"10.1056\/NEJMoa1504720"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Neal B, Perkovic V, Mahaffey KW, <i>et al<\/i>. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644-57.","DOI":"10.1056\/NEJMoa1611925"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Perkovic V, Jardine MJ, Neal B, <i>et al<\/i>. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295-306.","DOI":"10.1056\/NEJMoa1811744"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. McMurray JJV, Solomon SD, Inzucchi SE, <i>et al<\/i>. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381: 1995-2008.","DOI":"10.1056\/NEJMoa1911303"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, <i>et al<\/i>. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020; 383: 1436-46.","DOI":"10.1056\/NEJMoa2024816"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Anker SD, Butler J, Filippatos G, <i>et al<\/i>. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021; 385: 1451-61.","DOI":"10.1056\/NEJMoa2107038"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Packer M, Anker SD, Butler J, <i>et al<\/i>. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020; 383: 1413-24.","DOI":"10.1056\/NEJMoa2022190"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Bhatt DL, Szarek M, Pitt B, <i>et al<\/i>. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021; 384: 129-39.","DOI":"10.1056\/NEJMoa2030186"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Cannon CP, Pratley R, Dagogo-Jack S, <i>et al<\/i>. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020; 383: 1425-35.","DOI":"10.1056\/NEJMoa2004967"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Nadkarni GN, Ferrandino R, Chang A, <i>et al<\/i>. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care 2017; 40: 1479-85.","DOI":"10.2337\/dc17-1011"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nat Rev Nephrol 2016; 12: 711-2.","DOI":"10.1038\/nrneph.2016.159"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Szalat A, Perlman A, Muszkat M, Khamaisi M, Abassi Z, Heyman SN. Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia. Drug Saf 2018; 41: 239-52.","DOI":"10.1007\/s40264-017-0602-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Fralick M, Schneeweiss S, Patorno E. Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017; 376: 2300-2.","DOI":"10.1056\/NEJMc1701990"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors. J Diabetes Investig 2016; 7: 135-8.","DOI":"10.1111\/jdi.12401"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/2\/64_22-441\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T05:06:15Z","timestamp":1715317575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/64\/2\/64_22-441\/_article"}},"subtitle":["A Meta-Analysis Focusing on the Number Needed to Treat"],"short-title":[],"issued":{"date-parts":[[2023,3,31]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.22-441","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,31]]},"article-number":"22-441"}}